Second-Line Targeted Options Considered in ESR1-Mutated Breast Cancer

1 year ago 86

During a Case-Based Roundtable® event, Ruth M. O'Regan, MD, looks at options for a patients with hormone receptor–positive, HER2-negative breast cancer and an ESR1 mutation in the second article of a 2-part series.

1. Homepage
2. Breast Cancer
3. Second-Line Targeted Options Considered in ESR1-Mutated Breast Cancer